Owl Therapeutics, a wholly owned subsidiary of Gryphon Bio, entered into a global licensing and collaboration agreement with Swedish-based Abliva AB to advance Abliva's NeuroSTAT (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI).
Owl Therapeutics Enters a Strategic Clinical Collaboration With Abliva